These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651 [TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698 [TBL] [Abstract][Full Text] [Related]
27. Alternative donor hematopoietic stem cell transplantation for sickle cell disease. Gilman AL; Eckrich MJ; Epstein S; Barnhart C; Cannon M; Fukes T; Hyland M; Shah K; Grochowski D; Champion E; Ivanova A Blood Adv; 2017 Jul; 1(16):1215-1223. PubMed ID: 29296761 [TBL] [Abstract][Full Text] [Related]
28. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841 [TBL] [Abstract][Full Text] [Related]
30. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
31. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545 [TBL] [Abstract][Full Text] [Related]
32. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia]. Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
34. [A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients]. Lu QY; Zaho JN; Niu XQ; Wang Z; Cai YX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):154-7. PubMed ID: 21362242 [TBL] [Abstract][Full Text] [Related]
35. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248 [TBL] [Abstract][Full Text] [Related]
36. [Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia]. Sun C; Lin X; Huang Y; Song C; Tao Y; Tu S; Fang J; Chen T; Sun C; Wu B Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):221-4. PubMed ID: 24666488 [TBL] [Abstract][Full Text] [Related]
37. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705 [TBL] [Abstract][Full Text] [Related]
38. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia]. Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329 [No Abstract] [Full Text] [Related]